Compare
TScan Therapeutics, Inc. vs Alpha Cognition Inc. vs Caribou Biosciences, Inc. vs Curis Inc
| Latest fiscal year | TScan Therapeutics, Inc. TCRX | Alpha Cognition Inc. ACOG | Caribou Biosciences, Inc. CRBU | Curis Inc CRIS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $10.32M | $10.22M | $11.16M | $9.44M |
| Revenue growth (YoY) | +266.7% | n/a | +11.7% | -13.4% |
| Gross margin | n/a | 94.1% (computed) | n/a | n/a |
| Operating margin | n/m | -221.7% | n/m | -60.5% |
| Net margin | n/m | -202.2% | n/m | -80.3% |
| Net income | -$129.77M | -$20.67M | -$148.12M | -$7.58M |
| EPS (Diluted) | -$1.00 | -$1.18 | -$1.59 | -$0.58 |
| Operating cash flow | -$135.32M | -$20.38M | -$110.99M | -$27.20M |
| Free cash flow | -$139.73M | -$20.67M | -$112.35M | n/a |
| Cash & equivalents | $152.41M | $66.05M | $12.36M | $5.06M |
| Total assets | $228.79M | $79.73M | $175.37M | $19.97M |
| Total liabilities | $105.67M | $17.20M | $53.19M | $14.50M |
| Shareholders' equity | $123.12M | $62.53M | $122.17M | $5.46M |
| Return on year-end equity | -105.4% | -33.1% | -121.2% | -138.8% |
| Shares outstanding | n/a | 21.74M | 95.14M | 12.93M |
Revenue, most recent five fiscal years
| Fiscal year | TScan Therapeutics, Inc. | Alpha Cognition Inc. | Caribou Biosciences, Inc. | Curis Inc |
|---|---|---|---|---|
| Latest | $10.32M Ended 2025-12-31 | $10.22M Ended 2025-12-31 | $11.16M Ended 2025-12-31 | $9.44M Ended 2025-12-31 |
| 1 year earlier | $2.82M Ended 2024-12-31 | n/a | $9.99M Ended 2024-12-31 | $10.91M Ended 2024-12-31 |
| 2 years earlier | $21.05M Ended 2023-12-31 | n/a | $34.48M Ended 2023-12-31 | $10.02M Ended 2023-12-31 |
| 3 years earlier | $13.54M Ended 2022-12-31 | n/a | $13.85M Ended 2022-12-31 | $10.16M Ended 2022-12-31 |
| 4 years earlier | $10.14M Ended 2021-12-31 | n/a | $9.60M Ended 2021-12-31 | $10.65M Ended 2021-12-31 |